Stories

Two million adult Canadians should not become collateral damage in a policy designed around fear. Ottawa’s proposed vape flavour ban risks removing the products that many adults rely on to stay away from cigarettes. Science should guide regulation: protect young people through enforcement and age controls, but do not erase the flavours that help make switching work. A policy that punishes adult smokers for choosing a lower-risk option is not harm reduction.

Sometimes harm reduction begins with one person who refuses to give up on someone else. Behind the evidence, policy arguments and product categories are people who smoke, people who love them, and people trying to keep them alive long enough to find a safer path. Tobacco harm reduction is often discussed as a technical issue, but its urgency is deeply human. The goal is not to win an argument about nicotine — it is to reduce harm for real people.

Stability may sound like a technical detail, but it shapes whether a nicotine pouch performs consistently over time. Formula design can affect nicotine release, shelf life, user experience and the standards regulators should expect from smoke-free products. That makes product chemistry part of the public health conversation, not just a manufacturing issue. If nicotine pouches are to be regulated responsibly, evidence on formulation and stability should matter as much as assumptions about the category.

Two presentations can reveal one crisis when the same evidence points are interpreted in opposite ways. In nicotine policy, that crisis is not only about disagreement — it is about whether science is being used to clarify risk or to defend existing positions. When data on safer products is filtered through ideology, smokers may be left with confusion instead of useful guidance. Public health needs evidence that informs decisions, not evidence selected to protect a narrative.

A nicotine pouch is not a cigarette without smoke; it is a different product category altogether. That distinction matters for regulation, because rules designed around combustion do not automatically make sense for oral, smoke-free nicotine. Pouches still need standards, age controls and monitoring, but policy should reflect their actual risk profile rather than the stigma attached to cigarettes. Regulation is most credible when it recognises differences instead of flattening them.

Prohibition can give the impression of control while making the underlying risks harder to manage. When legal access to safer nicotine products is restricted, demand does not disappear; it can shift towards illicit supply, misinformation or continued cigarette use. That is where public health loses ground: not in the intention to reduce harm, but in the failure to account for real-world behaviour. Effective policy should reduce risk where people actually are, not where theory assumes they should be.

Safer nicotine did not appear out of nowhere. Its history is shaped by smokers looking for alternatives, scientists measuring risk, and policies that often struggled to keep up with both. From snus to vaping and nicotine pouches, the same lesson keeps returning: removing combustion can change the health equation. Understanding that history matters, because the future of tobacco policy should not repeat the mistakes that kept cigarettes at the centre for so long.

Italy and Greece challenge Ireland's proposed strict regulations on nicotine products, citing concerns about EU market coordination. The dispute centers on balancing public health goals with market harmonization. Ireland aims to enhance controls on vapes and nicotine pouches, focusing on marketing, packaging, and sales restrictions. This conflict highlights the evolving fragmentation of European nicotine regulations, affecting companies operating across the region. The objections emphasize the need for harmonizing national rules with EU frameworks. The debate underscores the challenges of aligning public health objectives with single market principles in the nicotine industry.

Surprise from the vaping sector points to a wider problem: policy is moving faster than the evidence conversation. When responsible retailers and manufacturers are treated as obstacles rather than part of the regulated solution, the legal market becomes weaker and the illicit market gains room. A serious approach should separate youth access, enforcement failures and adult switching instead of folding them into one blunt narrative. Regulation works best when it brings credible actors into accountability, not when it pushes them to the margins.

Cancer risk should not be discussed through headlines alone. New modelling on vaping and future cancer burden raises important questions about long-term outcomes, but it also depends on the comparison being made: continued smoking, complete cessation, dual use or full switching. The crucial distinction remains combustion, which drives the overwhelming burden of tobacco-related cancer. Public health communication should examine emerging risks without obscuring the far greater danger of cigarettes.